CytomX to Present at the 2017 Wedbush PacGrow Healthcare Conference
August 10 2017 - 4:05PM
CytomX Therapeutics, Inc. (Nasdaq:CTMX), a biopharmaceutical
company developing investigational Probody™ therapeutics for the
treatment of cancer, will present at the 2017 Wedbush PacGrow
Healthcare Conference. Debanjan Ray, chief financial officer
and head of corporate development will deliver a corporate overview
on August 16, 2017, at 2:30 p.m. ET.
A live audio webcast of the presentation will be available
through the Investors and News section of CytomX's website. An
archived replay will be available for 90 days following the
event.
About CytomX Therapeutics CytomX Therapeutics
is a clinical-stage biopharmaceutical company with a deep and
differentiated oncology pipeline of Probody™ therapeutics. Probody
therapeutics exploit unique conditions of the tumor
microenvironment to more effectively localize antibody binding and
activity while limiting activity in healthy tissues. The Company’s
pipeline includes proprietary cancer immunotherapies against
clinically-validated targets, such as PD-L1, and first-in-class
Probody drug conjugates against highly attractive targets, such as
CD166 and CD71, which are considered to be inaccessible to
conventional antibody drug conjugates due to their presence on
healthy tissue. In addition to its wholly owned programs, CytomX
has strategic collaborations with AbbVie, Bristol-Myers
Squibb Company, Pfizer Inc., MD Anderson Cancer
Center and ImmunoGen, Inc. For more information,
visit www.cytomx.com or follow us on Twitter.
Media Contact:
Spectrum
Christine Quern
cquern@spectrumscience.com
202-587-2588
Investor Contact:
Trout Group
Pete Rahmer
prahmer@troutgroup.com
646-378-2973
CytomX Therapeutics (NASDAQ:CTMX)
Historical Stock Chart
From Aug 2024 to Sep 2024
CytomX Therapeutics (NASDAQ:CTMX)
Historical Stock Chart
From Sep 2023 to Sep 2024